NCT07261891 Ex Vivo Evaluation of JAK-inhibitor and Gene Therapeutical Approach in JAK-STAT Related Disorders
| NCT ID | NCT07261891 |
| Status | Recruiting |
| Phase | — |
| Sponsor | prof. dr. Rik Schrijvers |
| Condition | Primary Immunodeficiency Diseases (PID) |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2024-11-21 |
| Primary Completion | 2028-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2024-11-21 with a primary completion date of 2028-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The investigators want to study the JAK-inhibitors and their impact on the immune system and evaluate the potential of a gene-therapeutic strategy
Eligibility Criteria
Inclusion Criteria: * Cases (A): adult patients presenting with a genetically confirmed or highly suspected disorder leading to an exagerated JAK-STAT pathway. * Controls (B): participants eligible for inclusion in this study must fall in one of the following categories: * Healthy controls (without immune-mediated disease) Exclusion Criteria: * Children (\< 18 years at time of recruitment) * Persons unable or unwilling to give informed consent
Contact & Investigator
Rik Schrijvers, MD, PhD
PRINCIPAL INVESTIGATOR
UZ Leuven
Frequently Asked Questions
Who can join the NCT07261891 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Primary Immunodeficiency Diseases (PID). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07261891 currently recruiting?
Yes, NCT07261891 is actively recruiting participants. Contact the research team at rik.schrijvers@uzleuven.be for enrollment information.
Where is the NCT07261891 trial being conducted?
This trial is being conducted at Leuven, Belgium.
Who is sponsoring the NCT07261891 clinical trial?
NCT07261891 is sponsored by prof. dr. Rik Schrijvers. The principal investigator is Rik Schrijvers, MD, PhD at UZ Leuven. The trial plans to enroll 20 participants.